SAN DIEGO–(BUSINESS WIRE)–Cortechs.ai Inc., the leading quantitative neuroimaging software company, announced today they will be exhibiting at Americas Committee for Treatment & Research in Multiple Sclerosis’ (ACTRIMS) 2020 annual forum, which is taking place from February 27-29, 2020. In addition to exhibiting LesionQuant’s ability to segment and quantify new, active and resolving lesions as well as gray and white matter on the floor at booth number 412, the company will present their findings from a recent study titled: “Performance Evaluation for Multiple Sclerosis Identification Models Based on MR Imaging and Machine Learning.” The company will also be participating jointly with The Consortium of Multiple Sclerosis Centers and other industry experts, in a presentation titled: “Updated Recommendations for a Standardized MRI Protocol for Multiple Sclerosis.”

In the study “Performance Evaluation for MS Identification Models”, Cortechs.ai used a recent version of their flagship product, NeuroQuant 3.0, to compute volumetric brain measurements to train an AI algorithm to create machine learning models for different age ranges to classify multiple sclerosis (MS) subjects. They evaluated the performance of these models for identifying MS subjects and studied the differences of feature importance selected by the models based on whole and specific age range data. The company will be presenting its findings at the conference around the understanding that studying volumetric changes in the brain can lead to a much deeper understanding of the effects and symptoms of MS as a disease, and that these models may be used as MS classifiers to assist clinicians in decision making.

“We are dedicated to improving patient outcomes and up-leveling the standard of patient care through best in class clinical applications and patient-centric analysis and reporting,” said Chris Airriess, Ph.D., chief executive officer of Cortechs.ai. “Having two very close friends with the disease, I have seen firsthand the impact MS can have on the lives of patients and their families. We work hard every day to provide software solutions to enable early, accurate diagnosis of MS to ultimately help patients get the treatment they need as soon as possible – and to monitor treatment response to ensure the best possible outcomes. The research being presented at ACTRIMS provides hope for furthering these advancements in the diagnosis and classification of MS.”

Cortechs.ai will have the following two poster presentations at ACTRIMS 2020:

• Friday February 28, 11:00 a.m.-12:00 p.m. ET: Performance Evaluation for Multiple Sclerosis Identification Models Based on MR Imaging and Machine Learning (Board No. P183). Presented by Weidong Luo, Ph.D., principal scientist.

• Session: Poster Session 2 Lunch

• Friday February 28, 12:00-1:00 p.m. ET: Updated Recommendations for a Standardized MRI Protocol for Multiple Sclerosis (Board No. LB310). Presented by The Consortium of MS Centers in partnership with select experts for their input and co-authorship, including Marilyn Maes, M.S., RT, clinical specialist and Amy Verrinder, vice president of sales.

• Session: Poster Session 2 Lunch

Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists and clinical researchers worldwide with a convenient and cost-effective means to quantify brain structures to help assess a variety of neurodegenerative conditions.

About Cortechs.ai
Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists and clinical researchers worldwide with a convenient and cost-effective means to quantify brain structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development abnormalities. Please visit cortechs.ai for further information and follow us on Twitter, LinkedIn and Facebook.

###